Neuraxis, INC (NRXS) — SEC Filings

Overview

Neuraxis, INC (NRXS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Neuraxis, Inc. (NRXS) reported a net loss of $2,122,796 for the three months ended September 30, 2025, an increase from a net loss of $1,755,234 in the prior year period. For the nine months ended September 30, 2025, the net loss was $6,091,898, an improvement from $6,793,596 in the same period of 2

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bearish, 32 neutral, 2 mixed. The dominant filing sentiment for Neuraxis, INC is neutral.

Filing Type Overview

Neuraxis, INC (NRXS) has filed 6 10-Q, 22 8-K, 2 DEF 14A, 2 10-K, 1 SC 13D, 2 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

• Neuraxis Sales Surge 35% Amid Rising Losses, Strategic License Recapture — 10-Q · Nov 10, 2025 Risk: high
  Neuraxis, Inc. (NRXS) reported a net loss of $2,122,796 for the three months ended September 30, 2025, an increase from a net loss of $1,755,234 in the prior ye
• Neuraxis, Inc. Files 8-K Current Report — 8-K · Oct 24, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on October 24, 2025, reporting an event on October 23, 2025. The filing is a current report under Section 13 or 15(d) of the Securit
• Neuraxis, Inc. Files 8-K on Operations — 8-K · Oct 23, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K report on October 23, 2025, to disclose information regarding its results of operations and financial condition. The filing does not
• Neuraxis, Inc. Signs Material Definitive Agreement — 8-K · Sep 2, 2025 Risk: medium
  Neuraxis, Inc. announced on August 29, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principal
• Neuraxis Narrows Losses Amid Strong Revenue Growth, Recaptures Key IP — 10-Q · Aug 12, 2025 Risk: medium
  Neuraxis, Inc. (NRXS) reported a net loss of $1,690,418 for the three months ended June 30, 2025, a significant improvement from the $2,917,710 net loss in the
• Neuraxis, Inc. Files 8-K with Material Agreements and Officer Changes — 8-K · Jul 3, 2025 Risk: medium
  Neuraxis, Inc. filed an 8-K on July 3, 2025, reporting on several key events as of July 1, 2025. These include entering into a material definitive agreement, te
• Neuraxis, Inc. Files 8-K on Shareholder Vote Matters — 8-K · Jun 4, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on June 4, 2025, reporting on matters submitted to a vote of security holders as of May 29, 2025. The filing details the company's c
• Neuraxis, Inc. Files 8-K with Corporate Updates — 8-K · May 28, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on May 23, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's princi
• Neuraxis, Inc. Files 8-K with Material Agreement — 8-K · May 22, 2025 Risk: medium
  On May 20, 2025, Neuraxis, Inc. entered into a material definitive agreement. The company also reported on other events and filed financial statements and exhib
• Neuraxis, Inc. Files 8-K for Material Agreement & Financial Obligation — 8-K · May 21, 2025 Risk: medium
  Neuraxis, Inc. announced on May 15, 2025, the entry into a material definitive agreement and the creation of a direct financial obligation. The company, incorpo
• Neuraxis, Inc. Files Q1 2025 10-Q — 10-Q · May 12, 2025 Risk: low
  Neuraxis, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including balance sh
• Neuraxis, Inc. Files Definitive Proxy Statement — DEF 14A · Apr 14, 2025 Risk: low
  Neuraxis, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 14, 2025, for its fiscal year ending December 31, 2025. The company, located in Carmel, Ind
• 10-K Filing — 10-K · Mar 20, 2025
• Neuraxis, Inc. Files 8-K on Financials — 8-K · Jan 8, 2025 Risk: low
  Neuraxis, Inc. filed an 8-K on January 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exh
• Rosalind Advisors Discloses 9.9% Stake in Neuraxis, Inc. — SC 13D · Dec 2, 2024 Risk: medium
  Rosalind Advisors, Inc. and its affiliates, including Aharon Gil and Rosalind Master Fund L.P., have filed a Schedule 13D on November 12, 2024, indicating they
• Neuraxis Appoints New Directors, Updates Executive Contracts — 8-K · Nov 25, 2024 Risk: low
  Neuraxis, Inc. announced on November 19, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors
• Neuraxis, Inc. Files 8-K: Rights, Bylaws, and Financials Updated — 8-K · Nov 21, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on November 21, 2024, reporting events as of November 15, 2024. The filing indicates material modifications to the rights of securit
• Neuraxis, Inc. Files 8-K on Material Agreement & Equity Sales — 8-K · Nov 15, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on November 15, 2024, reporting on events that occurred on November 9, 2024. The filing indicates the entry into a material definiti
• Neuraxis, Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 12, 2024 Risk: medium
  Neuraxis, Inc. filed its 10-Q for the period ending September 30, 2024. The company, located in Carmel, Indiana, operates in the electromedical and electrothera
• Neuraxis, Inc. Files 8-K on Material Agreement & Equity Sales — 8-K · Oct 18, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on October 18, 2024, reporting on events that occurred on October 12, 2024. The filing indicates the entry into a material definitiv
• SC 13G/A Filing — SC 13G/A · Oct 8, 2024
• Neuraxis Reports Unregistered Equity Sales — 8-K · Sep 13, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on September 13, 2024, reporting unregistered sales of equity securities on September 9, 2024. The filing does not specify the numbe
• Neuraxis, Inc. Files 8-K on Security Holder Votes and Exhibits — 8-K · Aug 21, 2024 Risk: low
  Neuraxis, Inc. filed an 8-K on August 21, 2024, reporting on events that occurred on August 15, 2024. The filing primarily concerns the submission of matters to
• Neuraxis, Inc. Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Neuraxis, Inc. filed its 10-Q for the period ending June 30, 2024. The company, located in Carmel, Indiana, operates in the electromedical and electrotherapeuti
• Neuraxis Appoints New Directors, Adjusts Executive Pay — 8-K · Jul 5, 2024 Risk: medium
  Neuraxis, Inc. announced on June 28, 2024, changes in its board of directors and executive compensation. The company appointed two new directors, Dr. David L. B
• Neuraxis Inc. Files Definitive Proxy Statement — DEF 14A · Jul 1, 2024 Risk: low
  Neuraxis, Inc. filed a definitive proxy statement (DEF 14A) on July 1, 2024, for its annual meeting on August 15, 2024. The company, incorporated in Delaware wi
• Neuraxis, Inc. Files 8-K for Material Definitive Agreement — 8-K · May 28, 2024 Risk: medium
  On May 21, 2024, Neuraxis, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware with
• Neuraxis, Inc. Files Q1 2024 10-Q Report — 10-Q · May 20, 2024 Risk: low
  Neuraxis, Inc. filed its 10-Q for the period ending March 31, 2024. The filing details financial information and business operations for the first quarter of 20
• Neuraxis, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 16, 2024 Risk: low
  Neuraxis, INC (NRXS) filed a Annual Report (10-K) with the SEC on April 16, 2024. Neuraxis, Inc. filed its 2023 Form 10-K on April 16, 2024, reporting on its fi
• Neuraxis Restates Financials Due to Reporting Errors — 8-K · Apr 9, 2024 Risk: high
  Neuraxis, Inc. announced on April 4, 2024, that it will not rely on previously issued financial statements for periods ending on or before December 31, 2023, an
• Neuraxis, Inc. Files 8-K for Material Definitive Agreement — 8-K · Mar 28, 2024 Risk: medium
  Neuraxis, Inc. announced on March 22, 2024, that it entered into a material definitive agreement. The company, incorporated in Delaware with its principal execu
• Neuraxis Appoints New CMO, Adds Directors — 8-K · Mar 11, 2024 Risk: low
  Neuraxis, Inc. announced on March 7, 2024, the appointment of Dr. David L. Bear as Chief Medical Officer and the election of Mr. David L. Bear and Ms. Sarah E.
• Neuraxis Enters Material Agreement, Incurs New Financial Obligation — 8-K · Feb 15, 2024 Risk: medium
  Neuraxis, Inc. filed an 8-K on February 15, 2024, reporting an event that occurred on February 9, 2024. The filing indicates the entry into a material definitiv
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Neuraxis, Inc. Changes Principal Executive Office Address — 8-K · Jan 31, 2024
  Neuraxis, Inc. filed an 8-K on January 31, 2024, reporting a change in its principal executive offices effective January 25, 2024. The company moved from 11550

Risk Profile

Risk Assessment: Of NRXS's 31 recent filings, 2 were flagged as high-risk, 16 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Neuraxis, INC's most recent 10-Q filing (Nov 10, 2025):

• Revenue: $2.60M
• Net Income: -$6.09M
• Cash Position: $4.38M

Key Executives

• Aharon Gil
• Dr. David E. Bear
• Mr. David M. Miller
• Dr. Jonathan M. Miller
• Mr. Michael J. Lytle
• Dr. David L. Bear
• Mr. Michael J. O'Neill
• Dr. Robert L. White
• Mr. David L. Bear
• Ms. Sarah E. Johnson

Industry Context

Neuraxis, Inc. operates in the medical device sector, which is characterized by innovation, stringent regulatory oversight, and significant competition. Companies in this space often require substantial R&D investment and aggressive marketing to gain market share. The trend towards specialized devices and digital health solutions continues to shape the industry landscape.

Top Tags

financials (9) · material-agreement (6) · 8-k (5) · corporate-governance (5) · 10-Q (4) · filing (3) · material-definitive-agreement (3) · equity-sale (3) · Medical Devices (2) · Neuromodulation (2)

Key Numbers

• Net Sales: $2.60M — Increased 35.1% for the nine months ended September 30, 2025, from $1.92M in 2024.
• Net Loss: $6.09M — Reduced from $6.79M in the prior nine-month period, but still substantial.
• Selling Expenses: $1.69M — Increased 67.3% for the nine months ended September 30, 2025, indicating aggressive marketing.
• Cash Used in Operating Activities: $4.49M — Increased from $4.34M in the prior nine-month period, highlighting ongoing cash burn.
• Cash and Cash Equivalents: $4.38M — Increased from $3.70M at December 31, 2024, primarily due to financing activities.
• Proceeds from Common Shares: $4.99M — Significant capital raised from issuance of common shares in the nine months ended September 30, 2025.
• Proceeds from Exercised Warrants: $1.00M — Additional capital raised from warrant exercises in the nine months ended September 30, 2025.
• NSS-2 Bridge License Termination: $200,000 — Consideration received for recapturing rights to the NSS-2 Bridge device.
• Accumulated Deficit: $62.89M — Indicates significant historical losses and a challenge to achieve profitability.
• Common Stock Outstanding: 10,652,812 — As of November 7, 2025, reflecting recent share issuances.
• Common Stock Shares Outstanding: 9,858,716 — Increased from 6,990,227 at Dec 31, 2024
• Gross Profit: $1,503,623 — For the six months ended June 30, 2025, up from $1,109,596 in 2024
• SEC File Number: 001-41775 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 45-5079684 — Company's tax identification number.
• I.R.S. Employer Identification No.: 45-5079684 — Company's tax identification number.

Related Companies

NRSX

Frequently Asked Questions